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Purpose: Anxiety disorders are frequently associated with chronic stress with 
possible cognitive consequences. The aim of this study was to determine the 
verbal fluency performance in a cohort of patients with anxiety disorders and 
allostatic load, treated with alprazolam during 12 weeks. Methods: Patients 
with GAD (general anxiety disorders, DSM IV), with >6 in Hamilton Anxiety 
Rating Scale (HAM-A), neuroticism > 18 (NEO-FFI inventory), and normal 
Mini-Mental State Examination were included. Clinical and Psychiatric ex-
amination, Allostatic Load Index and cognitive assessment were analyzed be-
fore and after 12 weeks of treatment. The phonemic and semantic verbal flu-
ency tests were determined in all patients. The scoring for each fluency task 
was determined by counting the number of correct words. The total score 
from each semantic and phonemic verbal task was analyzed comparing the 
individual score with normal data controlled by age and sex. Patients with 
scores > −2 standard deviation (SD) from normative data were considered 
impaired. Results: Fifty-four patients completed the semantic verbal fluency 
test before treatment and fifty patients completed after treatment. According 
to the z-scores before treatment 7 patients of 54 (12.9%) had verbal fluency 
impairments. After treatment none patients showed semantic verbal fluency 
deficits but 3 patients of 50 (6%) showed phonemic impairments. Impaired 
group was significantly associated with an older age before treatment (p = 
0.033) and with a similar tendency but not significant (p = 0.09) after treat-
ment (Student t test). Conclusion: In this study older age factor was associ-
ated with verbal fluency impairment in GAD patients. Stratified treatments 
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analyzing age and sex factors, including allostatic load measurements and 
cognitive assessments may be useful tools to determine the effectiveness and 
the safety of psychopharmacological treatments. 
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1. Introduction 
Stressors trigger physiological and behavioural responses that are aimed at 
reinstating homeostasis. If the stress response is inadequate or excessive and 
prolonged (chronic stress), the cost of reinstating homeostasis might become too 
high and predisposed individuals at an increased risk of (mental) illness such as 
general anxiety disorder [1] [2]. Chronic stress has been demonstrated to induce 
functionally-relevant effects on hippocampus and prefrontal cortex brain neuro-
plasticity due to hypothalamic-pituitary-adrenal axis (HPA)1 hyperactivity, tra-
duced on impairments in cognition [3]-[8].  
Verbal and non-verbal fluency performance have been previously studied in 
patients with attention deficit hyperactivity disorder [9] and in patients with 
obsessive compulsive disorder [10] and also in subjects with stress related condi-
tions such as neuroticism [11], showing lower scores and impairments among 
these patients. In this line, other authors have been proposed that anxiety may 
modify neural activation during the performance of verbal fluency tasks, execu-
tive functions that are dependent on the frontal lobe function [12].  
On the other side, the use of drugs such as benzodiazepines is effective in 
promptly reducing anxiety scores but may have controversial effects on cogni-
tion after long term use [13]-[18]. Nevertheless, there are not conclusive findings 
regarding verbal fluency, an executive function which depends on frontal lobe 
functions, in patients with general anxiety disorders treated with benzodiaze-
pines [18] [19].  
The rate of the outpatients’ use of benzodiazepines has been increased sub-
stantially in the last years, especially among clinicians, psychiatrists and neurol-
ogists [20]; indeed clinical studies are continually needed to determine safety in 
long term uses. The GEMA project (Gador Study of Stress Modulation by Al-
prazolam) [21] consists of a series of consecutive studies performed on a group 
of high symptomatic outpatients with general anxiety disorder (GAD)2 associ-
ated with chronic stress, determined by high allostatic load (AL) levels (indica-
tors for the functioning of the main potentially stress affected systems) [22] [23] 
and neuroticism (a clinical condition well-known as a stress vulnerability factor 
and defined as an exaggerated response to psychosocial stressors with intense 
emotional reaction) [24] [25] [26] [27].  
 
 
1(HPA) Hypothalamic-pituitary-adrenal axis. 
2(GAD) General Anxiety Disorder 
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In a previous analysis performed by our group in the same cohort of pa-
tients, we analyzed the AL index and determined the effects of sex and age on 
allostatic load variables before and after treatment [28]. In this study we found 
that female sex was associated with higher levels of anxiety with a better profile 
in the same allostatic load variables such as cardiovascular ones. Hereby, in the 
present report we aimed to determine the verbal fluency performance at basal 
conditions (before treatment) and after 12 weeks of treatment with alprazolam 
(a positive allosteric modulator of GABA A receptor), including sex and age as 
influential factors. 
2. Methods 
In this prospective study patients were recruited during 3 years up to 2014. The 
database is currently locked and subjected to multiple analyses. Inclusion criteria 
were Hamilton Anxiety Rating Scale (HAM-A)3 [29] > 6, a minimum score of 18 
points in the NEO-FFI neuroticism scale [30] and at least one positive criterion 
for AL load index modified from Seeman and Crimmins 2003 [22] (clinical ma-
nifestations were under personalized medical treatment and were stable). All pa-
tients had a normal performance in the Mini-Mental State Examination [31] 
with general good vision and hearing with or without the use of aids. Exclusion 
criteria were: subjects with depression and/or other comorbid diseases listed 
under axis I of the DSM-IV, (American Psychiatric Association, 1994), patients 
taking psychotropic drugs, sympathomimetic, corticosteroid and/or any other 
medication that might interact with alprazolam; persons who were hypersensi-
tive to drugs; with confirmed or suspected gestation; women likely to become 
pregnant during the study; patients with an important clinical condition that 
required treatment modification and that might interfere with the study treat-
ment or evaluation methods.  
The protocol was evaluated in accordance with the code of ethics of the World 
Medical Association (Declaration of Helsinki) and Argentine clinical practice 
guideline, by the Independent Ethics Committee of Foundation for Pharmaco-
logical Studies and Drugs, Buenos Aires and then submitted to the national reg-
ulatory authority (ANMAT, Disposition #61409-8) and to the provincial regula-
tory authority, under the responsibility of the Ministry of Health of Córdoba 
Province (Dossier #1296). The trial is also registered at WHO (Word Health 
Organization)4 trial registration data set. Results were reported to the Argentine 
regulatory agency ANMAT in accordance with regulations in force. All patients 
signed the informed consent form. 
2.1. Clinical Assessment 
In this trial all determinations were analyzed periodically (see Soria et al. 2005 
for details) [21]. In the present study, we report the changes in verbal fluency 
 
 
3(HAM-A) Hamilton Anxiety Rating Scale. 
4(WHO) World Health Organization. 
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tests and the correlations with clinical variables, after 12 weeks of treatment with 
reference to the basal status.   
Anxiety assessment: All patients included in this study met criteria for general 
anxiety disorder codified in Axis I of DSM IV (American Psychiatric Associa-
tion) [32], and psychiatric assessment was determined by experimented clinical 
psychiatrists. In all patients the HAM-A [29] of 14 items was determined, (>6 
points indicated anxiety and ≥15 points indicated moderate to severe anxiety).  
Allostatic Load assessment: For measuring AL index, 18 clinical and laborato-
ry parameters were determined during the morning (10 ± 1 hour AM). One 
point was added for each abnormal parameter up or under the cut off points ac-
cording to Crimmins and Seeman criteria modified (2) [1]: 1—Systolic blood 
pressure > 140 mmHg and/or; 2—diastolic pressure >90 mmHg; 3—BMI2 (body 
mass index) > 25; 4—waist-hip ratio (indexes of adipose tissue deposition) more 
than >1 in men and >0.8 in women; 5—total cholesterol > 200 mg/dl; 6—LDL 
(low density lipoprotein) > 120 mg/dl; 7—HDL (high density lipoprotein) > 37 
mg/dl; 8—total cholesterol/HDL ratio > 3.5 mg/dl; 9—triglycerides > 200 mg/dl; 
10—creatinine > 1.2 mg/dl; 11—albumin < 3.5 g/dl; 12—C-reactive protein (CRP) > 
7.1 mg/L; 13—fibrinogen > 400 mg/dl; 14—glycated hemoglobin > 6 mg/dl; 
15—salivary cortisol > 32 nM; 16—salivary methoxy-hydroxy-phenylglycol 
(MHPG) (noradrenaline metabolite) > 2750 nM; 17—serum dehy-
dro-epi-androsterone (DHEA) < 80 ng/ml in men and <35 ng/ml in women; 
18—serum noradrenaline levels > 100 pg/ml.  
Cognitive assessment: The phonemic and semantic verbal fluency tests were 
determined in all patients [33]. On the semantic verbal fluency task partici-
pants had to name as many animals as possible within two minutes. Words 
that were not identifiable as animals were considered rule violations and the 
examiner recorded all correct words. On the phonemic verbal fluency task the 
patients were asked to name within 2 minutes, as many different words as 
possible beginning with the letter p. Words beginning with another letter 
and/or perseverations were considered rule violations. The scoring for each 
fluency task was determined by counting the number off correct words ex-
cluding the number of rule violations and repetitions. The tests were applied 
after 6 hours since the last administration of alprazolam (nadir plasma). Cog-
nitive tests were blinded to the evaluator. In this report we analyzed the scores 
at two moments, before and after treatment. The total score from each seman-
tic and phonemic verbal tasks were analyzed comparing the individual score 
with normal data controlled by age and sex. Patients with scores > −2 standard 
deviation (SD) from normative data controlled by age and sex were considered 
impaired [33]. 
2.2. Treatment Instauration 
Patients admitted into the study were given alprazolam tablets (Alplax®, Gador 
SA, Buenos Aires; batch number 03730), in a flexible dosing regimen within 0.25 
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to 1 mg t.i.d. (three times a day), which enabled a dose-response analysis for the 
variables under investigation. Individual doses were determined according to 
clinical criteria by the researcher responsible for each patient, and the lowest ef-
fective dose was administered in each case. The alprazolam’s dosage schedule 
was maintained for 12 weeks. Subsequently, the investigator decided to continue 
or discontinue treatment. All participants have been warned about alprazolam’s 
depressant effects and the possible risks in activities that required alert. Alcohol 
consumption during the observational period was not recommended. Patients 
were also monitored to detect risk of suicide and/or overdose. All adverse events 
were monitored according to good clinical practice standards of the local regu-
latory authority; National Administration of Drugs, Foods and Medical Devices 
(ANMAT) and the Ministry of Health, Province of Córdoba.  
2.3. Statistics  
Descriptive statistics of quantitative variables were determined and compared. 
The sample size was calculated considering changes in variables higher than 25% 
with a 1-β power of 0 - 80 to be detected. Statistical significance was considered 
at p < 0.05 (2-sided; 1-β power ≥ 0.80). To analyze sex and age factors (≥ or <50 
years old) effects on total scores of cognitive parameters, a general univariate 
lineal model (Two-way ANOVA) was applied for each AL variable measured 
before and after treatment. Interactions between factors were also analyzed, and 
the effect size was calculated using the partial eta squared (hp2). Effect size > 0.09 
was considered strong, between 0.02 and 0.09 is moderate and ≤0.02 is statisti-
cally significant but weak. Student t test was determined to compare impaired 
versus no-impaired group. Spearman (non-parametric) and/or Pearson (para-
metric) tests were used to determine the correlation coefficient: r ≥ 0.80 and p < 
0.05 (2-sided) was considered as strong correlation, r = 0.50 < r < 0.80 and p < 
0.05 (2-sided), was considered a moderate correlation and r ≥ 0.3 and <0.5 and p < 
0.05 (2-sided) was considered a low correlation [34]. 
3. Results 
In this analysis, fifty-four patients completed the semantic verbal fluency test (35 
women and 19 men), and 53 (35 women and 18 men) the phonemic verbal flu-
ency test at basal. According age, at basal 26 patients had ≥50 years old, and 28 
patients < 50 years. After treatment fifty patients completed both semantic and 
phonemic verbal fluency tests. Changes in the individual allostatic variables in 
this sample and psychiatric variables were described in detail in a previous pub-
lication [28]. The VFT scores according age a sex are resumed in Table 1 and 
Table 2. No differences were found regarding sex and age factors in this sample 
analyzing the total score (Two way ANOVA) either at basal or at week 12. In a 
second analysis, the z-scores corrected by age and sex for each patient, were de-
termined before and after treatment. Before treatment 7 patients of 54 (12.9%) 
had verbal fluency impairments (z-score > −2 comparing with normative data  
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Table 1. Sex differences in cognitive performance before and after treatment. 




Sex n Χ SD 
Two-way  








Females 35 31.7 10.2 
3.7 (1,50) = 0.05 0.069 
Males 19 28.2 6.4 
w12 
Females 31 14.4 5.7 
8.82 (1,46) = 0.005* 0.161 
Males 19 9.4 5.8 
Total Allostatic Index  
Basal 
Females 35 5.4 2.3 
1.08 (1,50) = 0.30 0.021 
Males 19 6.0 2.2 
w12 
Females 31 4.6 2.5 
2.13 (1,46) = 0.15 0.044 
Males 19 5.4 1.9 




Females 35 20.0 5.2 
0.006 (1,50) = 0.94 0.001 
Males 19 20.0 4.8 
w12 
Females 31 23.5 5.0 
0.45 (1,46) = 0.23 0.03 
Males 19 25.3 6.3 




Females 35 12.9 3.9 
0.27 (1,49) = 0.6 0.006 
Males 18 12.1 4.8 
w12 
Females 31 14.52 4.1 
0.25 (1,46) = 0.6 0.021 
Males 19 13.74 3.5 
W12: Week 12, n (number of patients), X = mean, SD = standard deviation. hp2 = Effect size. *p < 0.05. 
 
matched by age and sex); 5 patients showed impairments in semantic verbal 
fluency, 2 patients in phonemic verbal fluency and 1 showed both semantic and 
phonemic impairments. After treatment none patients showed semantic verbal 
fluency deficits but 3 patients of 50 (6%) showed phonemic impairments (Figure 
1).  
In an ulterior analysis we compared the clinical variables (psychiatric, allos-
tatic load and pharmacological variables), between impaired and no-impaired 
subjects before and after treatment. Impaired group was significantly associated 
to older age before treatment (p = 0.033) with a tendency but not significant (p = 
0.09) after treatment (Student t test) (Figure 2). Pearson correlations between 
allostatic load individual parameters and verbal fluency tasks (z scores), showed 
a low correlation between phonemic verbal fluency and noradrenaline levels af-
ter treatment (r = 0.31, p = 0.03). Also a tendency to a negative correlation 
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Table 2. Age differences in cognitive performance before and after treatment. 




(Years = ys) 
n χ SD 
Two-way ANOVA 








≥50 ys 26 31.4 8.1 
0.01 (1,50) = 0.97 0.001 
<50 ys 28 30.9 8.3 
w12 
≥50 ys 24 13.1 6.4 
0.03 (1,46) = 0.90 0.000 
<50 ys 26 11.9 6.1 




≥50 ys 26 6.1 1.8 
3.31 (1,50) = 0.07 0.062 
<50 ys 28 5.1 2.4 
w12 
≥50 ys 24 5.7 2.1 
5.98 (1,46) = 0.02* 0.115 
<50 ys 26 4.1 2.3 




≥50 ys 26 19.7 5.9 
0.01(1,50) = 0.89 0.001 
<50 ys 28 20.3 4.1 
w12 
≥50 ys 24 24.4 5.8 
0.27(1,46) = 0.63 0.006 
<50 ys 26 24.0 5.3 




≥50 ys 26 12.1 4.1 
0.76(1,49) = 0.80 0.015 
<50 ys 27 13.1 4.4 
w12 
≥50 ys 24 14.5 4.3 
0.69(1,46) = 0.40 0.015 
<50 ys 26 13.9 3.5 
W12: Week 12, n (number of patients), X = mean, SD = standard deviation. hp2 = Effect size. *p < 0.05. 
 
was found between DHEA plasmatic levels (r = −027, p = 0.04) and phonemic 
verbal fluency z-score at basal (Figure 3). Additionally, Pearson correlations 
between verbal fluency tests, showed an inverse correlation tendency between 
neuroticism score and phonemic verbal fluency score at basal (r = −0.258, p = 
0.068). 
4. Discussion 
In this study we included a special sample of very symptomatic patients with 
GAD associated to AL (a clinical index of chronic stress) and neuroticism (a 
psychological condition associated to an exaggerated response to psychosocial 
stressors). These patients underwent long-term treatment (12 weeks) with al-
prazolam in low doses (1.5 to 3 mg/day). The high-potency BZD alprazolam (a 
triazolo-benzodiazepine), produces a positive allosteric modulation of GABAA  
C. A. Soria et al. 
 
 
DOI: 10.4236/ojpsych.2019.92011 145 Open Journal of Psychiatry 
 
 
Figure 1. Verbal Fluency Test (VFT), semantic and phonemic z-scores in function of the allostatic load index in 
patients with general anxiety disorder treated during 12 weeks with alprazolam. 
 
 
Figure 2. Age comparison of subjects with general anxiety disorder and allostatic load treated during 12 weeks 
with alprazolam according to the performance in the VFT (z-scores). Blue boxes represent patients with normal 
VFT (z-scores ≤ −2 SD), and orange boxes represent patients with impaired VFT (z-scores > −2 SD). 
 
receptor. Alprazolam administered in relatively low doses may has a positive ef-
fect on individuals with anxiety disorders associated with chronic stress, and has  
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Figure 3. Pearson correlations between cognitive variables (Phonemic VFT) and allostatic load variables. Pho-
nemic VFT inversely correlated with DHEA plasmatic levels at basal and positively correlated with noradrenaline 
plasmatic levels at 12 weeks. 
 
been proposed to have less impact on cognitive functions because of the shorter 
acting and the lower doses required [18] [21]. Nevertheless, the risk of inducing 
pharmacological dependence and/or cognitive adverse events have been de-
scribed, indeed it should be regarded with caution [13] [14] [15] [16] [17] [35] 
[36] [37]. In the present report, older age was the main factor involved in the 
verbal fluency alterations observed before and after alprazolam treatment. Before 
treatment a 13% was found impaired. After treatment, phonemic but not seman-
tic verbal fluency was found impaired in a few cases. Older age is a known factor 
involved in cognition impairment, and has been proposed as a warning factor 
for developing cognitive decline induced by drugs, particularly benzodiazepines 
[18] [36] [38]-[43]. Additionally, in this study, the noradrenaline levels showed a 
low correlation with verbal fluency scores after treatment, suggesting that nora-
drenergic function may be a potential regulator of these functions with a poten-
tial dual effect (deleterious effect in high levels but also in very low levels). Simi-
lar to this results, other researchers determined lower salivary levels of MHPG in 
anxious patients treated with alprazolam [24] [44] [45] and in normal subjects 
who received the drug [46]. Similarly to these authors, we described in a pre-
vious report the reduction of MHPG (the main noradrenaline metabolite) and 
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noradrenaline, 12 weeks after treatment with alprazolam, contributing to reduce 
AL [28]. In this regard an increment of noradrenergic function was described in 
patients with anxiety disorders [47] [48]. Indeed, periodic dosages of allostatic 
load biochemical parameters may be an easy method to complete the clinical 
analysis during the follow up of treated patients.  
Chronic stress has demonstrated to induce negative effects on cognitive func-
tions and on emotional regulation, altering neuroendocrine and autonomic 
functions [8]. Chronic stress may impairs cognitive function [49] and has nega-
tive effects on cerebral neuroplasticity affecting dendritic arbor and synapses 
number in specific brain regions, including the hippocampus, amygdala and the 
prefrontal cortex. Chronic elevated levels of glucocorticoids may reduce memory 
processes (declarative memory) by affecting the normal hippocampal neuroplas-
ticity and functionality [49] [50] [51]. Furthermore, stress-related events upon 
the prefrontal cortex may have deleterious actions in working memory (the 
short term memory that keep events in mind) which is also an executive func-
tion depending on frontal lobe normal functioning [52]. Not only chronic stress 
affects cognition, also anxiety by itself can modify executive functions. It has 
been proposed that anxiety as a personality trait reduces executive cognitive 
functions by impairing attention and task-switching capacity [53]. Gwada et al. 
recently found that low-anxious subjects showed an increased activation in the 
fronto-parietal networks, while highly anxious individuals showed a particular 
pattern of increased functioning of the cingulo-opercular and ventral attention 
favoring attention deficits [12]. In this study we did no found correlations be-
tween the severity of anxiety and verbal fluency but lower scores were found re-
lated to older age before treatment, in both semantic and phonemic verbal flu-
ency. This finding suggests that anxiety may affect differently cognitive func-
tions according age.  
Limitations of this study must be mentioned: In this observational study we 
did not included a parallel control group, which is not allowed in a phase IV trial 
with highly symptomatic patients with inherent risks. Indeed, we could not 
compare the learning curve to determine the cognitive differences before and af-
ter treatment.  
Cognitive tests were retested periodically during all the treatment period, 
principally to detect cognitive adverse events, nevertheless in this study we ana-
lyzed only at basal and at 12 weeks to determine the relationship within the clin-
ical variables inside each period (basal: anxiety without treatment, and 12 weeks 
with alprazolam treatment).  
5. Conclusions 
In this study older age factor was associated with verbal fluency impairment in 
GAD patients. 
Stratified treatments analyzing age and sex factors, including allostatic load 
measurements and cognitive assessments may be useful tools to determine the 
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effectiveness and the safety of psychopharmacological treatments. 
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